Lisa Carey, MD, ScM, FASCO
@DrLisaCarey
Followers
2K
Following
8
Media
12
Statuses
121
The Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research; Deputy Director of Clinical Sciences at @UNC_Lineberger
Chapel Hill, NC
Joined June 2020
In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.
In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiation did not reduce breast cancer recurrence or improve survival. Full results from a phase 3 trial: https://t.co/M5HIEFodxB
12
46
260
Standing ovation at @ASCO for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise effect from Challenge versus multiple drug effects.
3
56
195
TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents - -HER2+ or TN pts with MRD assay after NAT and pre surgery -in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis @hthrparsons @TheTBCRC @awolff @benhopark
0
10
20
SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! PFS2 + OS immature Could be a paradigm shift + could introduce ctDNA monitoring into practice https://t.co/eP2RKeK6QE
astrazeneca.com
2
44
132
PRO-B presentation - web-based patient-reported symptom management via app and alerts resulted not just in clinically meaningful fatigue improvement AND 29% better OS in MBC. If it was a drug it would be a blockbuster! #SABCS24 #bcsm @OncoAlert
2
9
29
Compelling evidence for this new SERD, and even more when combined with abemaciclib, including those with prior CDK4/6i.
#sabcs24. Congrats @jhaveri_komal on this excellent work! Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | New England Journal of Medicine @oncoalert.
0
2
9
Absolute benefit about 5% including node-negative. Important update as this drug moves towards adjuvant approval.
#ESMO24 Natalee 4 yr update with increasing benefit in all subgroups c/w carryover effect. 36% <3 yrs; 20% due to AEs. 8.6% gr 3+ LFTs AEs. Nitrosamine issue 2b imminently resolved. Exciting advance for mod/hi risk ES HR+ BC. @OncoAlert
0
3
15
In this recent Review, @prat_aleix @PTarantinoMD, @adawaksmd and co-authors discuss mechanisms of synergy, patient selection and resistance to dual HER2 blockade in patients with HER2-amplified tumours: https://t.co/c0nWullIDL
1
20
54
ABIGAIL (in HR+/HER2-) and the second IA of the DETECT-5 trial (in HR+/HER2+) both found no usefulness of induction chemo prior to starting an ET-based approach, calling into question a common practice. #ESMO2024 @OncoAlert
1
12
36
Great confirmation of the crucial role of pembrolizumab in early TNBC with a clear OS advantage.
Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert
0
2
16
Last night, BCRF's Chief Scientific Officer Dr. Dorraya El-Ashry announced a new BCRF-supported @ConquerCancerFd young investigator award in honor of our Founding Scientific Director Dr. Larry Norton. #ASCO24
0
3
9
Great synopsis! Key that the “HER2- ultralow” group appeared to benefit similarly, highlighting that immunostains are simply not designed for differentiating HER2 in the lowest registers!
@curijoey: DB06 novel LBA session #ASCO24. 60% in TPC received cape. Med FU 18 mo. 3% bone only. Most CDKi preTx. PFS HR 0.62 HER2 low. OS early. Ultralow HR 0.78 w/wide CI overlap 1. 2+ > 1+. ORR better! Grade 5 ILD 0.7%. New SOC 4 hi risk/visc Mets in HER2 low. @OncoAlert
0
1
4
#ASCO24—Let’s be impatient for our patients. We have a bottleneck of good science waiting to move into the clinic. If we are to #EndCancerAsWeKnowIt, clinical studies must be more accessible, nimble, inclusive, and designed to answer questions in the populations that need them.
0
31
93
So good to hear this remarkable speech at the ASCO opening meeting - salutary to think about when we doubtless will see endless slides later in the week of drug ‘break throughs’ showing marginal benefits for patients!
Terrific reminder from@ASCO president @ASCOPres Lynn Schuchter on the dignity of medical care and the promise to comfort always
0
2
7
Agree, but would also caution that we know that ER-low is heterogeneous including a significant minority that are luminal. This is why ASCO /CAP guidelines set the bar for ER and endocrine therapy at <1%. Today’s talk supports that decision but we need to get better assays!
Very nice work and congrats! Important to exercise caution in interpreting these results. Patients with pCR did not benefit and this is a very heterogenous disease - where summary data is reported. @OncoAlert
0
1
11
🌟It was great to speak with @DrLisaCarey of @UNC_Lineberger who discussed upcoming #BreastCancer updates from #ASCO24 ➡️Check out https://t.co/ys1d8pDAKO where we'll be publishing the full interview and more soon... @ASCO #ASCO24 #Oncology #BCsm @OncoAlert
0
3
4
So excited to add new leaders to the @ALLIANCE_org Patient Advocate Committee.. Vernal as VC for Health Disparities, Jane as VC for Cancer Control. #advocatesNCTN
Congratulations to Vernal Branch and Jane Perlmutter, PhD, MBA, on their appointments as Alliance Patient Advocate Committee Vice-Chairs! #AllianceSpring24 #NCI #NCTN #NCORP #CancerResearch
1
5
16
Wonderful piece for patients describing clinical trials and questions to ask!
A clinical trial is a research study that assesses the safety and effectiveness of a cancer treatment. This JAMA Oncology Patient Page explains clinical trials and what patients should consider regarding enrollment.
0
12
36
Tucatinib added to TDM1 mostly 2L and 40% CNS+ improved PFS by 2.1m in HER2CLIMB02. Unknown about added to TDXd (standard 2L) but…#1 may be better combo than tuc + cape/H (esp CNS+) and #2 supports COMPASSHER2-RD trial! @SABCSSanAntonio
0
3
12